Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer

NCT04176081 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

208

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Darolutamide
DRUG: Degarelix
RADIATION: Radiation Therapy

Sponsor

University Health Network, Toronto

Collaborators

[object Object]
[object Object]